Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 623

1.

New Fissure-attached Nodules in Lung Cancer Screening: A Brief Report from The NELSON Study.

Han D, Heuvelmans MA, van der Aalst CM, van Smoorenburg LH, Dorrius MD, Rook M, Nackaerts K, Walter JE, Groen HJM, Vliegenthart R, de Koning HJ, Oudkerke M.

J Thorac Oncol. 2019 Oct 10. pii: S1556-0864(19)33521-X. doi: 10.1016/j.jtho.2019.09.193. [Epub ahead of print]

PMID:
31606605
2.

A comparative modeling analysis of risk-based lung cancer screening strategies.

Ten Haaf K, Bastani M, Cao P, Jeon J, Toumazis I, Han SS, Plevritis SK, Blom EF, Kong CY, Tammemägi MC, Feuer EJ, Meza R, de Koning HJ.

J Natl Cancer Inst. 2019 Sep 30. pii: djz164. doi: 10.1093/jnci/djz164. [Epub ahead of print]

PMID:
31566216
3.

Growth of hepatocellular adenoma during pregnancy: a prospective study.

Gaspersz MP, Klompenhouwer AJ, Broker MEE, Thomeer MGJ, van Aalten SM, Steegers E, Terkivatan T, de Koning H, de Man RA, Ijzermans JNM.

J Hepatol. 2019 Sep 21. pii: S0168-8278(19)30548-3. doi: 10.1016/j.jhep.2019.09.011. [Epub ahead of print]

PMID:
31550458
4.

Investigation of 5'-Norcarbocyclic Nucleoside Analogues as Antiprotozoal and Antibacterial Agents.

Khandazhinskaya AL, Matyugina ES, Solyev PN, Wilkinson M, Buckheit KW, Buckheit RW Jr, Chernousova LN, Smirnova TG, Andreevskaya SN, Alzahrani KJ, Natto MJ, Kochetkov SN, de Koning HP, Seley-Radtke KL.

Molecules. 2019 Sep 21;24(19). pii: E3433. doi: 10.3390/molecules24193433.

5.

Incidence of Interval Colorectal Cancer After Negative Results From First-Round Fecal Immunochemical Screening Tests, by Cutoff Value and Participant Sex and Age.

Toes-Zoutendijk E, Kooyker AI, Dekker E, Spaander MCW, Opstal-van Winden AWJ, Ramakers C, Buskermolen M, van Vuuren AJ, Kuipers EJ, van Kemenade FJ, Velthuysen MF, Thomeer MGJ, van Veldhuizen H, van Ballegooijen M, Nagtegaal ID, de Koning HJ, van Leerdam ME, Lansdorp-Vogelaar I; Dutch National Colorectal Cancer Screening Working Group.

Clin Gastroenterol Hepatol. 2019 Aug 20. pii: S1542-3565(19)30896-1. doi: 10.1016/j.cgh.2019.08.021. [Epub ahead of print]

6.

All-cause mortality versus cancer-specific mortality as outcome in cancer screening trials: A review and modeling study.

Heijnsdijk EAM, Csanádi M, Gini A, Ten Haaf K, Bendes R, Anttila A, Senore C, de Koning HJ.

Cancer Med. 2019 Oct;8(13):6127-6138. doi: 10.1002/cam4.2476. Epub 2019 Aug 18.

7.

European propolis is highly active against trypanosomatids including Crithidia fasciculata.

Alotaibi A, Ebiloma GU, Williams R, Alenezi S, Donachie AM, Guillaume S, Igoli JO, Fearnley J, de Koning HP, Watson DG.

Sci Rep. 2019 Aug 6;9(1):11364. doi: 10.1038/s41598-019-47840-y.

8.

Benefits and Harms of Mammography Screening for Women With Down Syndrome: a Collaborative Modeling Study.

Alagoz O, Hajjar A, Chootipongchaivat S, van Ravesteyn NT, Yeh JM, Ergun MA, de Koning HJ, Chicoine B, Martin B.

J Gen Intern Med. 2019 Aug 5. doi: 10.1007/s11606-019-05182-5. [Epub ahead of print]

PMID:
31385214
9.

The role of modelling in the policy decision making process for cancer screening: example of prostate specific antigen screening.

Getaneh AM, Heijnsdijk EA, de Koning HJ.

Public Health Res Pract. 2019 Jul 31;29(2). pii: 2921912. doi: 10.17061/phrp2921912.

10.

Discovery of novel Schistosoma mansoni PDE4A inhibitors as potential agents against schistosomiasis.

Sebastián-Pérez V, Schroeder S, Munday JC, van der Meer T, Zaldívar-Díez J, Siderius M, de Koning HP, Brown D, Martínez A, Campillo NE, Leurs R, Gil C.

Future Med Chem. 2019 Jul;11(14):1703-1720. doi: 10.4155/fmc-2018-0592. Epub 2019 Aug 2.

PMID:
31370708
11.

Effect of screening mammography on breast cancer mortality: Quasi-experimental evidence from rollout of the Dutch population-based program with 17-year follow-up of a cohort.

Van Ourti T, O'Donnell O, Koç H, Fracheboud J, de Koning HJ.

Int J Cancer. 2019 Jul 22. doi: 10.1002/ijc.32584. [Epub ahead of print]

PMID:
31330046
12.

Alkynamide phthalazinones as a new class of TbrPDEB1 inhibitors.

de Heuvel E, Singh AK, Edink E, van der Meer T, van der Woude M, Sadek P, Krell-Jørgensen MP, van den Bergh T, Veerman J, Caljon G, Kalejaiye TD, Wijtmans M, Maes L, de Koning HP, Jan Sterk G, Siderius M, de Esch IJP, Brown DG, Leurs R.

Bioorg Med Chem. 2019 Sep 15;27(18):3998-4012. doi: 10.1016/j.bmc.2019.06.027. Epub 2019 Jun 18.

13.

The future is prosperous.

de Koning HJ.

J Natl Cancer Inst. 2019 Jul 11. pii: djz139. doi: 10.1093/jnci/djz139. [Epub ahead of print] No abstract available.

PMID:
31292643
14.

The influence of health systems on breast, cervical and colorectal cancer screening: an overview of systematic reviews using health systems and implementation research frameworks.

Priaulx J, Turnbull E, Heijnsdijk E, Csanádi M, Senore C, de Koning HJ, McKee M.

J Health Serv Res Policy. 2019 Jul 8:1355819619842314. doi: 10.1177/1355819619842314. [Epub ahead of print] No abstract available.

15.

MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial.

Saadatmand S, Geuzinge HA, Rutgers EJT, Mann RM, de Roy van Zuidewijn DBW, Zonderland HM, Tollenaar RAEM, Lobbes MBI, Ausems MGEM, van 't Riet M, Hooning MJ, Mares-Engelberts I, Luiten EJT, Heijnsdijk EAM, Verhoef C, Karssemeijer N, Oosterwijk JC, Obdeijn IM, de Koning HJ, Tilanus-Linthorst MMA; FaMRIsc study group.

Lancet Oncol. 2019 Aug;20(8):1136-1147. doi: 10.1016/S1470-2045(19)30275-X. Epub 2019 Jun 17.

PMID:
31221620
16.

Plusoptix photoscreener use for paediatric vision screening in Flanders and Iran.

Bostamzad P, Horwood AM, Schalij-Delfos NE, Boelaert K, de Koning HJ, Simonsz HJ.

Acta Ophthalmol. 2019 Jun 14. doi: 10.1111/aos.14144. [Epub ahead of print]

PMID:
31197950
17.

Evaluating Parameter Uncertainty in a Simulation Model of Cancer Using Emulators.

de Carvalho TM, Heijnsdijk EAM, Coffeng L, de Koning HJ.

Med Decis Making. 2019 May;39(4):405-413. doi: 10.1177/0272989X19837631. Epub 2019 Jun 10.

PMID:
31179833
18.

Antileishmanial and antitrypanosomal activity of symmetrical dibenzyl-substituted α,β-unsaturated carbonyl-based compounds.

Alkhaldi AA, de Koning HP, Bukhari SNA.

Drug Des Devel Ther. 2019 Apr 24;13:1179-1185. doi: 10.2147/DDDT.S204733. eCollection 2019.

19.

Towards determination of power loss at a rowing blade: Validation of a new method to estimate blade force characteristics.

Lintmeijer LL, Onneweer JPT, Hofmijster MJ, Wijgergangs WA, de Koning H, Clairbois B, Westerweel J, Grift EJ, Tummers MJ, van Soest AJ.

PLoS One. 2019 May 9;14(5):e0215674. doi: 10.1371/journal.pone.0215674. eCollection 2019.

20.

The Impact of Design and Performance in Prostate-Specific Antigen Screening: Differences Between ERSPC Centers.

Heijnsdijk EAM, Adolfsson J, Auvinen A, Roobol MJ, Hugosson J, de Koning HJ.

Eur Urol. 2019 Sep;76(3):276-279. doi: 10.1016/j.eururo.2019.04.007. Epub 2019 Apr 26.

PMID:
31031050
21.

Informed decision-making based on a leaflet in the context of prostate cancer screening.

Dierks T, Heijnsdijk EAM, Korfage IJ, Roobol MJ, de Koning HJ.

Patient Educ Couns. 2019 Aug;102(8):1483-1489. doi: 10.1016/j.pec.2019.03.009. Epub 2019 Apr 13.

PMID:
31014933
22.

Impact of a cardiovascular disease risk screening result on preventive behaviour in asymptomatic participants of the ROBINSCA trial.

Denissen SJ, van der Aalst CM, Vonder M, Oudkerk M, de Koning HJ.

Eur J Prev Cardiol. 2019 Aug;26(12):1313-1322. doi: 10.1177/2047487319843396. Epub 2019 Apr 9.

PMID:
30966821
23.

Isolation of a Novel Flavanonol and an Alkylresorcinol with Highly Potent Anti-Trypanosomal Activity from Libyan propolis.

Siheri W, Ebiloma GU, Igoli JO, Gray AI, Biddau M, Akrachalanont P, Alenezi S, Alwashih MA, Edrada-Ebel R, Muller S, Lawrence CE, Fearnley J, Watson DG, De Koning HP.

Molecules. 2019 Mar 15;24(6). pii: E1041. doi: 10.3390/molecules24061041.

24.

A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.

Hugosson J, Roobol MJ, Månsson M, Tammela TLJ, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Carlsson SV, Talala KM, Lilja H, Denis LJ, Recker F, Paez A, Puliti D, Villers A, Rebillard X, Kilpeläinen TP, Stenman UH, Godtman RA, Stinesen Kollberg K, Moss SM, Kujala P, Taari K, Huber A, van der Kwast T, Heijnsdijk EA, Bangma C, De Koning HJ, Schröder FH, Auvinen A; ERSPC investigators.

Eur Urol. 2019 Jul;76(1):43-51. doi: 10.1016/j.eururo.2019.02.009. Epub 2019 Feb 26.

PMID:
30824296
25.

Treatment capacity required for full-scale implementation of lung cancer screening in the United States.

Blom EF, Ten Haaf K, Arenberg DA, de Koning HJ.

Cancer. 2019 Jun 15;125(12):2039-2048. doi: 10.1002/cncr.32026. Epub 2019 Feb 27.

26.

Novel Minor Groove Binders Cure Animal African Trypanosomiasis in an in Vivo Mouse Model.

Giordani F, Khalaf AI, Gillingwater K, Munday JC, de Koning HP, Suckling CJ, Barrett MP, Scott FJ.

J Med Chem. 2019 Mar 28;62(6):3021-3035. doi: 10.1021/acs.jmedchem.8b01847. Epub 2019 Mar 13.

PMID:
30763102
27.

Alternative oxidase inhibitors: Mitochondrion-targeting as a strategy for new drugs against pathogenic parasites and fungi.

Ebiloma GU, Balogun EO, Cueto-Díaz EJ, de Koning HP, Dardonville C.

Med Res Rev. 2019 Sep;39(5):1553-1602. doi: 10.1002/med.21560. Epub 2019 Jan 29. Review.

PMID:
30693533
28.

The individual components of commercial isometamidium do not possess stronger trypanocidal activity than the mixture, nor bypass isometamidium resistance.

Eze AA, Igoli J, Gray AI, Skellern GG, De Koning HP.

Int J Parasitol Drugs Drug Resist. 2019 Apr;9:54-58. doi: 10.1016/j.ijpddr.2019.01.003. Epub 2019 Jan 21.

29.

Revisiting tubercidin against kinetoplastid parasites: Aromatic substitutions at position 7 improve activity and reduce toxicity.

Hulpia F, Campagnaro GD, Scortichini M, Van Hecke K, Maes L, de Koning HP, Caljon G, Van Calenbergh S.

Eur J Med Chem. 2019 Feb 15;164:689-705. doi: 10.1016/j.ejmech.2018.12.050. Epub 2018 Dec 21.

PMID:
30677668
30.

Imidazole Derivatives as Promising Agents for the Treatment of Chagas Disease.

de Araújo JS, García-Rubia A, Sebastián-Pérez V, Kalejaiye TD, Bernardino da Silva P, Fonseca-Berzal CR, Maes L, De Koning HP, Soeiro MNC, Gil C.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02156-18. doi: 10.1128/AAC.02156-18. Print 2019 Apr.

31.

Screening of a PDE-focused library identifies imidazoles with in vitro and in vivo antischistosomal activity.

Botros SS, William S, Sabra AA, El-Lakkany NM, Seif El-Din SH, García-Rubia A, Sebastián-Pérez V, Blaazer AR, de Heuvel E, Sijm M, Zheng Y, Salado IG, Munday JC, Maes L, de Esch IJP, Sterk GJ, Augustyns K, Leurs R, Gil C, De Koning HP.

Int J Parasitol Drugs Drug Resist. 2019 Apr;9:35-43. doi: 10.1016/j.ijpddr.2019.01.001. Epub 2019 Jan 14.

32.

Discovery of Sustainable Drugs for Neglected Tropical Diseases: Cashew Nut Shell Liquid (CNSL)-Based Hybrids Target Mitochondrial Function and ATP Production in Trypanosoma brucei.

Cerone M, Uliassi E, Prati F, Ebiloma GU, Lemgruber L, Bergamini C, Watson DG, de A M Ferreira T, Roth Cardoso GSH, Soares Romeiro LA, de Koning HP, Bolognesi ML.

ChemMedChem. 2019 Mar 22;14(6):621-635. doi: 10.1002/cmdc.201800790. Epub 2019 Feb 5.

33.

Quality Monitoring of a FIT-Based Colorectal Cancer Screening Program.

Toes-Zoutendijk E, Bonfrer JMG, Ramakers C, Thelen M, Spaander MCW, Dekker E, van der Meulen MP, Buskermolen M, van Vuuren AJ, Kuipers EJ, van Kemenade FJ, van Velthuysen MF, Thomeer MGJ, van Veldhuizen H, van Ballegooijen M, de Koning HJ, van Leerdam ME, Lansdorp-Vogelaar I.

Clin Chem. 2019 Mar;65(3):419-426. doi: 10.1373/clinchem.2018.294041. Epub 2019 Jan 16.

PMID:
30651228
34.

Potent Antitrypanosomal Activities of 3-Aminosteroids against African Trypanosomes: Investigation of Cellular Effects and of Cross-Resistance with Existing Drugs.

Nnadi CO, Ebiloma GU, Black JA, Nwodo NJ, Lemgruber L, Schmidt TJ, de Koning HP.

Molecules. 2019 Jan 12;24(2). pii: E268. doi: 10.3390/molecules24020268.

35.

Persisting new nodules in incidence rounds of the NELSON CT lung cancer screening study.

Walter JE, Heuvelmans MA, Ten Haaf K, Vliegenthart R, van der Aalst CM, Yousaf-Khan U, van Ooijen PMA, Nackaerts K, Groen HJM, De Bock GH, de Koning HJ, Oudkerk M.

Thorax. 2019 Mar;74(3):247-253. doi: 10.1136/thoraxjnl-2018-212152. Epub 2018 Dec 27.

PMID:
30591535
36.

Relationship between the number of new nodules and lung cancer probability in incidence screening rounds of CT lung cancer screening: The NELSON study.

Walter JE, Heuvelmans MA, de Bock GH, Yousaf-Khan U, Groen HJM, van der Aalst CM, Nackaerts K, van Ooijen PMA, de Koning HJ, Vliegenthart R, Oudkerk M.

Lung Cancer. 2018 Nov;125:103-108. doi: 10.1016/j.lungcan.2018.05.007. Epub 2018 May 14.

37.

A choice experiment to identify the most important elements of a successful cancer screening program according to those who research and manage such programs.

Priaulx J, Csanádi M, de Koning HJ, McKee M.

Int J Health Plann Manage. 2019 Jan;34(1):e34-e45. doi: 10.1002/hpm.2697. Epub 2018 Oct 31.

PMID:
30378696
38.

Modeling in Colorectal Cancer Screening: Assessing External and Predictive Validity of MISCAN-Colon Microsimulation Model Using NORCCAP Trial Results.

Buskermolen M, Gini A, Naber SK, Toes-Zoutendijk E, de Koning HJ, Lansdorp-Vogelaar I.

Med Decis Making. 2018 Nov;38(8):917-929. doi: 10.1177/0272989X18806497. Epub 2018 Oct 20.

PMID:
30343626
39.

SAR of 4-Alkoxybenzoic Acid Inhibitors of the Trypanosome Alternative Oxidase.

Meco-Navas A, Ebiloma GU, Martín-Domínguez A, Martínez-Benayas I, Cueto-Díaz EJ, Alhejely AS, Balogun EO, Saito M, Matsui M, Arai N, Shiba T, Harada S, de Koning HP, Dardonville C.

ACS Med Chem Lett. 2018 Jul 31;9(9):923-928. doi: 10.1021/acsmedchemlett.8b00282. eCollection 2018 Sep 13.

40.

Cloning and characterisation of the Equilibrative Nucleoside Transporter family of Trypanosoma cruzi: ultra-high affinity and selectivity to survive in the intracellular niche.

Campagnaro GD, de Freitas Nascimento J, Girard RBM, Silber AM, de Koning HP.

Biochim Biophys Acta Gen Subj. 2018 Dec;1862(12):2750-2763. doi: 10.1016/j.bbagen.2018.08.015. Epub 2018 Aug 24.

PMID:
30251664
41.

A health systems approach to identifying barriers to breast cancer screening programmes. Methodology and application in six European countries.

Turnbull E, Priaulx J, van Ravesteyn NT, Heinävaara S, Siljander I, Senore C, Segnan N, Vokó Z, Hagymásy J, Jarm K, Veerus P, de Koning HJ, McKee M.

Health Policy. 2018 Nov;122(11):1198-1205. doi: 10.1016/j.healthpol.2018.08.003. Epub 2018 Aug 24.

PMID:
30195444
42.

The health impact of human papillomavirus vaccination in the situation of primary human papillomavirus screening: A mathematical modeling study.

Matthijsse SM, Naber SK, Hontelez JAC, Bakker R, van Ballegooijen M, Lansdorp-Vogelaar I, de Kok IMCM, de Koning HJ, van Rosmalen J, de Vlas SJ.

PLoS One. 2018 Sep 4;13(9):e0202924. doi: 10.1371/journal.pone.0202924. eCollection 2018.

43.

Identifying the barriers to effective breast, cervical and colorectal cancer screening in thirty one European countries using the Barriers to Effective Screening Tool (BEST).

Priaulx J, de Koning HJ, de Kok IMCM, Széles G, McKee M.

Health Policy. 2018 Nov;122(11):1190-1197. doi: 10.1016/j.healthpol.2018.08.004. Epub 2018 Aug 27.

PMID:
30177278
44.

Results of a health systems approach to identify barriers to population-based cervical and colorectal cancer screening programmes in six European countries.

Turnbull E, Priaulx J, de Kok IMCM, Lansdorp-Vogelaar I, Anttila A, Sarkeala T, Senore C, Segnan N, Csanádi M, Pitter J, Novak Mlakar D, Ivanus U, Veerus P, de Koning HJ, McKee M.

Health Policy. 2018 Nov;122(11):1206-1211. doi: 10.1016/j.healthpol.2018.08.005. Epub 2018 Aug 24.

PMID:
30170757
45.

Cyclic Nucleotide-Specific Phosphodiesterases as Potential Drug Targets for Anti-Leishmania Therapy.

Sebastián-Pérez V, Hendrickx S, Munday JC, Kalejaiye T, Martínez A, Campillo NE, de Koning H, Caljon G, Maes L, Gil C.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e00603-18. doi: 10.1128/AAC.00603-18. Print 2018 Oct.

46.

Cost-effectiveness of surveillance schedules in older adults with non-muscle-invasive bladder cancer.

Heijnsdijk EAM, Nieboer D, Garg T, Lansdorp-Vogelaar I, de Koning HJ, Nielsen ME.

BJU Int. 2019 Feb;123(2):307-312. doi: 10.1111/bju.14502. Epub 2018 Aug 27.

47.

Cost-effectiveness of low-dose CT screening for lung cancer in a European country with high prevalence of smoking-A modelling study.

Tomonaga Y, Ten Haaf K, Frauenfelder T, Kohler M, Kouyos RD, Shilaih M, Lorez M, de Koning HJ, Schwenkglenks M, Puhan MA.

Lung Cancer. 2018 Jul;121:61-69. doi: 10.1016/j.lungcan.2018.05.008. Epub 2018 May 26.

PMID:
29858029
48.

New Subsolid Pulmonary Nodules in Lung Cancer Screening: The NELSON Trial.

Walter JE, Heuvelmans MA, Yousaf-Khan U, Dorrius MD, Thunnissen E, Schermann A, Groen HJM, van der Aalst CM, Nackaerts K, Vliegenthart R, de Koning HJ, Oudkerk M.

J Thorac Oncol. 2018 Sep;13(9):1410-1414. doi: 10.1016/j.jtho.2018.05.006. Epub 2018 Jul 12.

49.

Reasons for (non)participation in supplemental population-based MRI breast screening for women with extremely dense breasts.

de Lange SV, Bakker MF, Monninkhof EM, Peeters PHM, de Koekkoek-Doll PK, Mann RM, Rutten MJCM, Bisschops RHC, Veltman J, Duvivier KM, Lobbes MBI, de Koning HJ, Karssemeijer N, Pijnappel RM, Veldhuis WB, van Gils CH.

Clin Radiol. 2018 Aug;73(8):759.e1-759.e9. doi: 10.1016/j.crad.2018.04.002. Epub 2018 Jun 18.

PMID:
29759590
50.

Cost-effectiveness and budget impact analyses of a colorectal cancer screening programme in a high adenoma prevalence scenario using MISCAN-Colon microsimulation model.

Arrospide A, Idigoras I, Mar J, de Koning H, van der Meulen M, Soto-Gordoa M, Martinez-Llorente JM, Portillo I, Arana-Arri E, Ibarrondo O, Lansdorp-Vogelaar I.

BMC Cancer. 2018 Apr 25;18(1):464. doi: 10.1186/s12885-018-4362-1.

Supplemental Content

Loading ...
Support Center